COMBAT - Updated biosecurity tool with 4 features
The Guilty Gilt Guide
PRRS Ctrl 2.0
The 11th European PRRS Research Awards
The objective of the present study was to explore the benefits of Porcine circovirus 2 (PCV-2) blanket vaccination in a sow herd on productive parameters, PCV-2 infection and immune status in sows and their progeny.
“The antibodies generated by some old vaccine strains have their neutralising capability reduced by the new PPV”
Porcine reproductive and respiratory syndrome (PRRS) causes substantial financial losses in pig farms and economic losses to societies worldwide. Vaccination against PRRS virus (PRRSV) is a common intervention in affected farms.
Porcine respiratory and reproductive syndrome virus (PRRSV) is a major swine pathogen responsible for immense economic loss annually. PRRSV first emerged in North America in the late 1980's in near synchrony with its emergence in Europe as the etiological agent of a novel potent swine disease. Not long after, the virus spread to or was detected in most swine rearing countries making it a problem of global relevance. To date, the evolutionary origin of PRRSV is not known although retrospective serologic screening in herds has indicated the virus circulated in pigs for at least several years prior to its official recognition or "emergence". Several hypotheses have been put forth attempting to explain the advent of PRRS however each has its shortcomings.
Don’t miss any news on PRRS disease control Subscribe now to PRRS.com newsletter
Meet the Expert Bite Sizes with Kristian Havn.
Vaccination of growing piglets under field conditions
Type 2 porcine reproductive and respiratory syndrome (PRRS) virus (PRRSV) was first isolated in Korea in 1994. The commercial PRRS modified live vaccine (Ingelvac1 PRRS MLV, Boehringer Ingelheim Vetmedica Inc., St. Joseph, Missouri, USA) based on type 2 PRRSV, was first licensed for use in 3- to 18-week-old pigs in Korea in 1996.